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Systemiclupuserythematosus(SLE)isaprototypicinﬂammatoryautoimmunedisordercharacterizedbymultisysteminvolvement
and ﬂuctuating disease activity. Symptoms range from rather mild manifestations such as rash or arthritis to life-threatening end-
organ manifestations. Despite new and improved therapy having positively impacted the prognosis of SLE, a subgroup of patients
do not respond to conventional therapy. Moreover, the risk of fatal outcomes and the damaging side eﬀects of immunosuppressive
therapies in SLE call for an improvement in the current therapeutic management. New therapeutic approaches are focused on B-
cell targets, T-cell downregulation and costimulatory blockade, cytokine inhibition, and the modulation of complement. Several
biological agents have been developed, but this encouraging news is associated with several disappointments in trials and provide
a timely moment to reﬂect on biologic therapy in SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune,
multisystemic, relapsing, and remitting disease that is char-
acterized by the production of antibodies against nuclear
antigens. The pathogenesis includes genetic, environmental,
and hormonal factors, but the cause of SLE remains unclear.
A broad array of clinical manifestations ranging from muco-
cutaneous and arthritis to severe organ- and life-threatening
disease are observed in SLE patients [1, 2].
The current treatment options include the use of corti-
costeroids, hydroxychloroquine, and other immunosuppres-
sive medications (e.g., azathioprine, mycophenolate, and
cyclophosphamide) [2]. More recently, belimumab was ap-
proved by the FDA for SLE treatment [3].
Due to earlier diagnosis and better treatment options of
both disease and complications, the prognosis has markedly
improved in the last decades. The 5-year survival of patients
with SLE has exceeded 90% in most centers [4, 5]. How-
ever, morbidity, especially renal failure, and mortality from
cardiovascular events after long-term followup are still an
important issue [5].
In the last decade new treatment strategies have been
developed. Advanced knowledge of the pathogenesis of SLE
has led to new therapeutic approaches targeting speciﬁc
molecules [4]. Beside autoantibody production, B-cells are
the key for the activation of the immune system, particularly
throughcytokinesandasantigen-presentingcells.Animpor-
tantpartofB-cellsisactivatedinaT-cell-dependantmanner.
This paper will review the rational of biologic therapies
in SLE and discuss potential therapeutic options.
2.B-CellTargets
B cells have been largely implicated in the pathogenesis of
SLE as sources of autoantibody, as antigen-presenting cells,
and as initiators and regulators of inﬂammation through
cytokine secretion [6–8]. B-cell-targeted therapies, including
anti-CD20 monoclonal antibody (Rituximab) and anti-B
lymphocyte stimulator (BLyS), are at forefront of new SLE
therapies [8, 9]( Table 1).
2.1. Anti-CD20 Antibody. The ﬁrst B-cell depleting antibody
used in SLE was rituximab, a chimeric murine/human mon-
oclonal antibody againstCD20 (Figure 1). CD20 is expressed
early in the development of B lymphocytes. Rituximab
administration results in rapid depletion of CD20-positive
Bl y m p h o c y t e s[ 7, 38, 39]. After rituximab treatment some
patients reconstitute with naive B cells and enter remission.2 International Journal of Rheumatology
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Figure 1: Potential targets and relevant drugs in connection with B and T cells in the management of SLE.
Others, however, do not deplete B cells completely and they
reconstitutewithmemoryBcellsandmight thereforebeneﬁt
from rituximab retreatment [10]. Two recent open-label
studies conﬁrmed that repeated cycles of rituximab are eﬀec-
tive in treating refractory SLE, may produce a sustained cli-
nical response and have a favorable safety proﬁle [10, 11].
Rituximab has been used in open trials and improve-
ments in disease activity has been observed [12, 13]. In addi-
tion it has been shown to be safe and well tolerated [13,
40, 41]. Two large multicenter randomized placebo-controll-
ed trials with rituximab in moderately to severely active SLE
(EXPLORER) [14] and in proliferative lupus nephritis pa-
tients (LUNAR) [15] could not demonstrate a signiﬁcant
beneﬁt of rituximab when compared to placebo. The inclu-
sion of milder forms of SLE, the ethnic background of pa-
tients, the concomitant use of steroids and other immuno-
suppressive drugs, and the short followup (52 weeks) could
explain in part why no beneﬁt could be demonstrated for
rituximab in these studies [14, 15, 42]. Despite the lack of
evidence in randomized trials, rituximab has been used in
refractory patients and improvement in up to 89% of the
patients has been observed [43–47].
Adverse events associated with the use of rituximab are
most often mild, but infusion reactions (30–35%), neutro-
penia (8%), and human antichimeric antibodies (9%) pro-
d u c t i o nh a v eb e e no b s e r v e d[ 10]. In addition, two cases of
fatal progressive multifocal leukoencephalopathy (lethal en-
cephalitis caused by the polyomavirus JC) in SLE patients
after rituximab treatment have been reported [11].
New monoclonal anti-CD20 antibodies have been devel-
oped. Ocrelizumab, a recombinant humanized monoclonal
anti-CD20 antibody has been studied in Phase III trials in
extrarenal SLE (BEGIN study) [16] and lupus nephritis
(BELONG study) [17]. However, treatment with ocrelizu-
mab has been suspended in SLE trials, following the negative
outcome of a similar study design with the anti-CD20 anti-
body and also due to an increase in the treatment group
[16, 17, 48].
2.2. Anti-CD22 Antibodies. Epratuzumab is a fully humaniz-
ed antibody against CD22. CD22 is 128a 135-kD B-lympho-
cyterestrictedtypeItransmembranesialoglycoproteinofthe
Ig superfamily and modulates B-cell function without B-cell
depletion[9,49].Epratuzumabwasevaluatedinrandomized
controlled trials in patients with moderate-to-severe SLE
ﬂares [18]. An improvement in BILAG scores and reduction
in corticosteroid doses with a good safety proﬁle was ob-
served; however the trial was interrupted due to problems in
the biologic supply [18]. Twostudies are currently evaluating
the eﬃcacy of epratuzumab in a subset of serologically active
SLE, and results have yet not been presented [19, 20].
2.3. B-Lymphocyte Tolerogens. Abetimus (LJP-394) is a B-cell
tolerogen. It consists of four double-stranded DNA (dsDNA)
epitopesonapolyethyleneglycolplatform[50].Itcross-links
anti-dsDNA surface immunoglobulin receptors on B-cells,
leading to anergy or apoptosis. It also reduces titers of anti-
dsDNA antibodies [21]. Abetimus was the ﬁrst B-cell tolero-
gen developed for SLE and was studied in human trials for
the treatment of nonrenal lupus and lupus nephritis [21].
Initial trials suggested a reduction in renal ﬂares in patients
who have high-aﬃnity antibodies to the DNA epitope con-
tainedwithintheabetimusmolecule[4,21].AfterananalysisInternational Journal of Rheumatology 3
Table 1: Biological therapies proposed for SLE treatment.
Biologic drug Main results
B-cell targets
Anti-CD20 antibody
Rituximab
Eﬀective in treating refractory SLE
[10, 11]
Improvements in disease activity
[12, 13]
No beneﬁt in proliferative lupus
nephritis [14, 15]
Ocrelizumab No beneﬁt in lupus nephritis [16, 17]
Anti-CD22 antibody
Epratuzumab
Improvement in BILAG scores [18]
R e d u c t i o ni nc o r t i c o s t e r o i dd o s e sw i t h
a good safety proﬁle [19, 20]
B-lymphocyte tolerogens
Abetimus No long-term beneﬁt in patients with
lupus nephritis [21]
Edratide No results released [22]
BLyS blockers
Belimumab Reduction in activity and new ﬂares
[23]
Atacicept Signiﬁcant decrease in IgM and IgG
levels [24]
T-cell target and costimulatory blockers
Abatacept Improvements in non-life- threatening
SLE manifestations [25, 26]
IDEC-131 No clinically eﬀective in human SLE
[27]
Efalizumab Reduction in cutaneous SLE
manifestations [28]
AMG557 No results released [29]
Sirolimus Safe and eﬀective for refractory SLE
[30]
Cytokine inhibition
Anti-TNF-α
Inﬂiximab Long-term eﬃcacy for lupus nephritis
[31]
Anti-IFN-α/-γ
Sifalimumab
Rontalizumab
AMG 811
No results released [32]
No results released [33]
No results released [34]
Anti-IL-1
Anakinra Improvements in SLE arthritis [35]
Anti-IL-6
Tocilizumab Improvements in clinical and serologic
responses [36]
Anti-IL-10
B-N10a Improvements in disease activity [37]
aMurine Lupus; BILAG: The British Isles Lupus Assessment Group; BLyS: B
cell survival molecule B lymphocyte stimulator; Ig: immunoglobulin; TNF:
tumor necrosis factor; INF: interferon; IL:interleukin.
of a phase III Abetimus Sodium in patients with a history of
lupus nephritis (ASPEN) trial, the trial was terminated when
interim eﬃcacy analysis indicated no beneﬁt to continue
[51].
Another tolerogen, TV-4710 (Edratide) a peptide com-
posedof19aminoacidsbasedonthecomplementarilydeter-
mining regions (CDR1) of a human anti-dsDNA antibody,
was tested in a phase II trial [22]. This study has been con-
cluded but there are yet no results released [22].
2.4. BLyS Blockers. T h eB - c e l ls u r v i v a lm o l e c u l eB - l y m p h o -
cyte stimulator (BLyS) also known as B-cell activation factor
of the TNF family (BAFF) plays a key role in the activation
and diﬀerentiation of B cells [4]. BLyS represents, therefore,
anexcellenttargetforinterventionsinSLE.Highserumlevels
of soluble BLyS, and its homolog APRIL (a proliferation in-
ducing ligand), are found in SLE patients and in murine
lupus. Selective blockade of BLyS reduces transitional type
2 follicular and marginal-zone B cells and signiﬁcantly atten-
uates immune activation [4, 9].
Belimumab is a fully human monoclonal antibody that
binds to BLyS and inhibits its biological activity (Figure 1).
Eﬃcacy, tolerability, and safety of three diﬀerent doses of
belimumab in SLE were evaluated in a multicenter phase II
study[23].After52weeksofanalysis,belimumabwasassoci-
atedwithareductioninactivityandnewﬂares.TwophaseIII
trials (BLISS-52 and BLISS-76) showed that belimumab plus
standard care achieved a signiﬁcant improvement in patient
responserateandincreasedtimeto-ﬁrst-ﬂarecomparedwith
placebo plus standard care [23, 52]. Based on these results,
FDA recently approved Belimumab for the treatment of SLE
[3].
An alternative blocker to BlyS is atacicept (also known as
TACI-Ig). It is a soluble transmembrane activator and cal-
cium-modulator and cyclophilin ligand interactor (TACI)
receptor, which binds both BAFF and APRIL (Figure 1). In
a phase I trial in SLE patients, atacicept was well tolerated
[24].
Atacicept is of interest in SLE because of its profound
eﬀectsonplasmacells,butitsuseleadstosigniﬁcantdecrease
in IgM and IgG immunoglobulin levels [53, 54]. A phase II
study of atacicept plus mycophenolate in SLE nephritis was
terminated because of an increased number of infections
[53]. The increased number of infection could be explained
by the fact that plasma cells require APRIL and so serum Ig
was reduced. A phase II/III trial of atacicept for generalized
SLE (April SLE) is still ongoing [55].
3. T-Cell Target and Costimulatory Blockers
Costimulatorymoleculesprovidethenecessarysecondsignal
for T-cell activation by antigen-presenting cells. The inhibi-
tionofthismechanismhasbeendemonstratedtobeeﬀective
in murine lupus models [56, 57]. The most important anti-
gen-independent signal for T-cell activation is the CD28:B7
costimulatory interaction [4]. CD28 is expressed on T cells,
whereas the ligands B7-1 and B7-2 (CD80 and CD86) are
found on antigen-presenting cells [4]. CTLA4 inhibits T-cell
activation by binding to B7-1 and B7-2 (CD80 and CD86)
expressed on antigen-presenting cells. Therefore CTLA4
interacts with B7 but inhibits T-cell activation, by preventing
the costimulatory signal CD28-B7 interaction necessary for
T-cell activation [4]( Figure 1).4 International Journal of Rheumatology
Abatacept is a soluble receptor or fusion protein encoded
by fusion of CTLA-4 with the Fc portion of IgG1. Abat-
acept blocks CD28-B7 interaction and subsequent T-cell-de-
pendent B-cell function [58, 59]( Figure 1). In murine
model, abatacept prevents initiation but not evolution of
antiphospholipid syndrome in NZW/BXSB mice [59]. In
SLE patients, abatacept has been tested in phase I to III trials
[25, 26].
CD40-CD40 ligand (CD40L) is another important cos-
timulatory pair that induces T-cell-dependent B-cell prolif-
eration and antibody production. CD40 is expressed on B
cells,endothelialcells,andantigen-presentingcellsandbinds
to CD40L (or CD154) on CD4+ T helper cells [4]( Figure 1).
In lupusprone mice with nephritis treated with anti-CD40L
antibodies reduction in anti-dsDNA antibody, milder renal
disease and increased survival was observed [60]. Unfortun-
ately, anti-CD40L monoclonal antibody (mAb) (IDEC-131)
didnotprovetobeclinicallyeﬀectiveinhumanSLEcompar-
edwithplacebo[27].Anotherstudy(BG9588)wasterminat-
ed prematurely after a few patients demonstrated life-threa-
tening prothrombotic events despite improvement in sero-
logic activity [61].
Efalizumab is a monoclonal antibody directed against
CD11a, the alpha-subunit of the leukocyte-functioning anti-
gen-1. It plays an important role in T-cell activation, re-acti-
vation, extravasation, and traﬃcking from the circulation
into the skin, through its binding to intercellular adhesion
molecules (Figure 1). Efalizumab seems to reduce cutaneous
manifestations in SLE patients [28]. The majority of patients
with diﬃcult lupus discoid had an important response to
treatment with the mean time to response being 5.5 week
[28]. However, this study evaluated only a small number of
patients. There is a need for more prospective studies with
long-term followup to better deﬁne the eﬃcacy and safety of
efalizumab in SLE.
The inducible costimulator (ICOS) is a T-cell-speciﬁc
molecule structurally and functionally related to CD28.
ICOSregulatesT-cellactivationandT-helpercelldiﬀerentia-
tion and is mainly involved in humoral immune responses
and, thus, autoantibody production. A fully humanized anti-
B7RP1 antibody (AMG557) is currently being investigated
and may represent a further target for SLE therapy [29].
Mammalian target of rapamycin (mTOR) has multiple
regulatory functions in T- and B-cell intracellular signaling
[62]. It controls the expression of T-cell receptor-associated
signaling proteins through increased expression of the endo-
some recycling regulator genes and enhances intracellular
calcium ﬂux [63]. Rapamycin (Sirolimus) interacts with
mTOR by inﬂuencing gene transcription and multiple cellu-
lar metabolic pathways. This interaction has been proven to
be beneﬁcial in murine lupus [64]. Rapamycin appeared to
be a safe and eﬀective therapy for refractory SLE in a small
pilot study [30].
4. CytokineInhibition
As cytokine dysregulation can be demonstrated in murine
and in SLE patients, an anticytokine approach seems
promising in this autoimmune disease [65]. Cytokines such
astumornecrosisfactoralpha(TNF-α),interferonalphaand
gamma (IFN-α/-γ) and interleukins (IL) 1, 6, 10, 15, and 18
are upregulated in SLE and play important roles in the inﬂa-
mmatory processes that leads to tissue and organ damage
[65]. These cytokines have been considered potential targets
for the reduction of chronic inﬂammation in SLE (Figure 1).
4.1. Anti-TNF-α. TNF-α is a pleiotropic cytokine that exerts
several functions in the immune system and can either pro-
mote or reduce autoimmunity. In SLE, its role is controver-
sial. TNF-α promotes apoptosis and signiﬁcantly aﬀects the
activity of B and T cells and dendritic cells (DCs). In diﬀe-
rent strains of lupus mice, the expression of TNF-α is often
variable, and beneﬁcial eﬀects on the disease can be observed
either after administration of TNF-α or upon TNF-α block-
ade [31, 66–68]. TNF-α blockers are associated with the de-
velopment of autoantibodies, such as antinuclear, anti-
dsDNA, and anticardiolipin, as well as with rare cases of
drug-induced lupuslike syndromes, all of which disappear
after therapy is discontinued [65].
There are several TNF-α inhibitors available for clinical
usesuchasinﬂiximab,adalimumab,golimumab,andcertoli-
zumab pegol and a fusion protein that acts as a “decoy recep-
tor” for TNF-α (etanercept) [31, 69]( Figure 1). TNF-α inhi-
bitors are usually well tolerated; however their use may in-
crease the overall risk of opportunistic infections, in parti-
cular the reactivation of latent tuberculosis [70, 71]. The ap-
pearance of neutralizing antibodies has been described in
patients treated with inﬂiximab, which is a chimeric human/
mouse mAb, as well as in those treated with adalimumab, in
spite of its fully human sequence [71]. The concomitant use
of an immunosuppressive drug like methotrexate has been
showntopreventthedevelopmentofneutralizingantibodies
[72].
4.2. Anti-IFN-α/-γ. IFN-α plays a signiﬁcant role in the
pathogenesisofSLE.IFN-γ iselevatedin(NewZealandBlack
[NZB] × New Zealand White [NZW]) F1 (NZB/W) lupus
mice, and a correlation with disease activity has been observ-
ed [73, 74]. In addition, administration of IFN-γ accelerates
murine lupus, while anti-IFN-γ antibody (or soluble IFN-
γ receptor or IFN-γ receptor-immunoglobin) delays the dis-
ease[75–77].Finally,ithasbeendemonstratedthatlatetreat-
ment with IFN-γ in MRL/lpr mice accelerates SLE, while
early treatment protects disease progression [78]. IFN-α
levels are increased in SLE patients and correlate with dis-
ease activity and kidney involvement [79]. In addition an in-
creased expression of interferon-regulated inﬂammatory
genes in the peripheral blood mononuclear cells of the SLE
patients(knownas“interferonsignature”)hasbeenobserved
[80, 81].
Sifalimumab (MEDI-545) is a monoclonal human anti-
body that blocks multiple IFN-α s u b t y p e s .I ti sc u r r e n t l y
being tested in phase I/II clinical trials to evaluate safety and
tolerability of multiple intravenous and subcutaneous doses
in SLE [32]( Figure 1).
Rontalizumab,ahumanizedmAbagainstIFN-α(rhuMAb
IFN-α) is in a phase II, randomized, double-blind,International Journal of Rheumatology 5
placebo-controlled trial that evaluates the eﬃcacy and safety
in patients with moderately to severely active SLE [33]
(Figure 1).
AMG811,ahumanmAbtoIFN-γ,isunderinvestigation
in a phase Ib, randomized, multicenter study in SLE patients
with and without glomerulonephritis [34].
4.3. Anti-IL-1. IL-1 levels are increased by serum TNF levels
and by anti-dsDNA antibody. The increase in serum IL-1
level is associated with lupus disease activity and a low level
of IL-1 receptor antagonist is seen in patients with lupus
nephritis [82, 83]. Anakinra, a nonglycolysated version of
the human IL-1Ra (IL-1 receptor antagonist), neutralizes the
biological activity of IL-1 (Figure 1). It has been used as an
alternative in individual patients with lupus arthritis not res-
ponding to conventional treatments [35]. Anakinra has
shown both safety and eﬃcacy in improving arthritis in an
open trial on four SLE patients, however short-lasting thera-
peutic eﬀects were observed in two patients [35].
4.4. Anti-IL-6. IL-6 induces B-cell diﬀerentiation to plasma
cells, hyperactivity, and secretion of antibodies and also pro-
m o t e sT - c e l lp r o l i f e r a t i o n ,c y t o t o x i cT - c e l ld i ﬀerentiation,
and local inﬂammation [65]. IL-6 is highly expressed in pa-
tients with lupus nephritis. IL-6 is induced in DCs by nucleic
acid containing immune complexes as well as by multiple
cytokines, including TNF, IL-1, and IFN-γ. In NZB/W mice
IL-6 promotes disease, and anti-IL-6 therapy delays lupus
nephritis, suggesting that IL-6 blockade might also be bene-
ﬁcial in SLE patients [84].
TocilizumabisahumanizedIgG1antibodydirectedtohu-
manIL-6receptorthatinhibitsIL-6signaling[85](Figure 1).
An open-label, dose escalating phase I study of tocilizumab
in SLE patients has recently been published [36]. Although
neutropenia may limit the maximum dosage of tocilizumab
in SLE patients, the observed clinical and serologic responses
are promising and warrant further studies to establish the
optimal dosing regimen and eﬃcacy [36].
4.5. Anti-IL-10. IL-10 is produced by Th2 cells and consider-
ed an inhibitory cytokine for T cells and contrasts the acti-
vity of other proinﬂammatory cytokines such as TNF-α and
IFN-γ. In SLE patients, IL-10 levels are increased in sera and
are associated with disease activity [50]. NZB/W mice treat-
ed with anti-IL-10 mAb have reduced anti-dsDNA antibody
titers and a delay in the onset of proteinuria and glomeru-
lonephritis [86].
In the absence of a humanized mAb to IL-10, the mu-
rine anti-IL-10 mAb (B-N10) was used to inhibit the activity
of IL-10 in a small uncontrolled, open-label study in SLE
patients with relatively mild disease [37]( Figure 1). Disease
activityimprovedandinactivitywasobservedinSLEpatients
up to 6 months after treatment. However, all patients de-
veloped antibodies against the murine mAb [37].
4.6. Anti-IL-15. IL-15 is mainly produced by the macro-
phage/monocytecellline[87].HighserumlevelsofIL-15are
found in 40% of SLE patients; however its levels are not
directly associated with disease activity [87]. IL-15 might be
responsible for some immune abnormalities of the disease,
such as stimulating lymphocytic expression of B-cell lym-
phoma 2 (Bcl-2) and CD25 (in both B and T-cells) [87].
Therapeutic agents against IL-15 are currently being tested
in other autoimmune diseases.
4.7. Anti-IL-18. IL-18 is a proinﬂammatory cytokine closely
relatedtoIL-1.Severalgroupshaveobservedincreasedserum
levels of IL-18 in SLE patients, which appear to be associated
with TNF levels [88–90]. IL-18 is overexpressed in the neph-
ritic kidneys of MRL/lpr mice. Moreover, MRL/lpr mice
beneﬁt from targeting IL-18 [91]. Until now, IL-18 blockade
has not been used in human SLE (Figure 1).
5. Complement Inhibition
The complement system consists of 3 pathways and more
than 30 proteins, including those with biological activity that
directly or indirectly mediate complement eﬀects, plus a set
of regulatory proteins necessary to prevent inadvisable com-
plement activation [9]. The complement system appears to
haveaprotectiveeﬀectinSLE,sincehomozygousdeﬁciencies
of classic pathway components are associated with an in-
creased risk for SLE. The deposition of immune complexes,
however, observed in human and animal models, leads to an
activation of the complement system, amplifying the inﬂam-
matory response. Pathologic evidence of immune complex-
mediated activation of complement in aﬀected tissues is
clearly evident in both experimental and human SLE [92].
Two complement inhibitors, soluble complement recep-
tor 1 (TP10) and a monoclonal anti-C5 antibody (Eculizu-
mab)havebeenshowntoinhibitcomplementsafelyandnow
are being investigated in a variety of clinical conditions [9].
Eculizumab has shown to reduce hemolysis and has been
approved by the FDA in paroxysmal nocturnal hemoglobin-
uria [93]. Although still no clinical trial has been performed
in SLE, they hold promise to be used therapeutically in SLE
[93].
6. Conclusion
In recent years advances in our understanding of the mech-
anisms of SLE has oﬀered better drug targets for treatment.
Over the next years, we will test the eﬃcacy of many new
therapeutic agents. The knowledge on how to divide patients
into subsets according to genetic susceptibility, pathogenetic
mechanisms, and phases of the disease will maximize the
therapeutic eﬀect of each agent and minimize its toxicity.
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